Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00962065 · ClinicalTrials.gov registry record · Phase 2
Study of LX4211 in Subjects With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00962065 is a Phase 2 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 36 participants.
The verdict
NCT00962065, a Phase 2 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of LX4211 versus a placebo control in subjects with type 2 diabetes mellitus.
Interventions
- DRUG Placebo
- DRUG LX4211 Low Dose
- DRUG LX4211 High Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00962065
The ClinicalTrials.gov registry entry for NCT00962065 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexicon Pharmaceuticals, which has 56 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00962065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00962065 about?
NCT00962065 is a clinical study titled "Study of LX4211 in Subjects With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the safety, tolerability, and efficacy of LX4211 versus a placebo control in subjects with type 2 diabetes mellitus.
What is the current status of trial NCT00962065?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2009-08.
What interventions are being tested in trial NCT00962065?
The interventions under investigation include: Placebo (DRUG), LX4211 Low Dose (DRUG), LX4211 High Dose (DRUG).
Who is sponsoring clinical trial NCT00962065?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.